Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer
14 nov. 2023 07h00 HE
|
Amydis, Inc.
Amydis Receives $3.4 million NIH Grant Award to Map Heterogeneity of Alzheimer’s in Human Clinical Trial Using Novel Retinal Tracer
Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta
02 nov. 2023 07h00 HE
|
Amydis, Inc.
Amydis announces Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
Accarent Health to Offer GRAIL’s Galleri®, a Multi-Cancer Early Detection Test to its Network and Members
02 oct. 2023 10h45 HE
|
Accarent Health
Baltimore, MD, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Accarent Health announced today the availability of Galleri®, a multi-cancer early detection (MCED) screening test to its network of patients,...
Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
22 sept. 2022 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting CNS biomarkers in the eye, today...
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD
18 août 2022 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
04 avr. 2022 07h00 HE
|
Amydis, Inc.
SAN DIEGO, April 04, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a healthcare company developing a new class of molecular retinal diagnostics and digital biomarkers to accelerate the early detection and...